Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Company News for Nov 7, 2024 [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.